Logo image of BCT.CA

BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Fundamental Analysis

TSX:BCT - Toronto Stock Exchange - CA1079302081 - Common Stock - Currency: CAD

4.71  +0.17 (+3.74%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BCT. BCT was compared to 24 industry peers in the Biotechnology industry. Both the profitability and financial health of BCT have multiple concerns. BCT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCT had negative earnings in the past year.
BCT had a negative operating cash flow in the past year.
In the past 5 years BCT always reported negative net income.
BCT had a negative operating cash flow in each of the past 5 years.
BCT.CA Yearly Net Income VS EBIT VS OCF VS FCFBCT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -197.40%, BCT is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -197.4%
ROE N/A
ROIC N/A
ROA(3y)-73.12%
ROA(5y)-202.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCT.CA Yearly ROA, ROE, ROICBCT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCT.CA Yearly Profit, Operating, Gross MarginsBCT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, BCT has more shares outstanding
The number of shares outstanding for BCT has been increased compared to 5 years ago.
There is no outstanding debt for BCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCT.CA Yearly Shares OutstandingBCT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
BCT.CA Yearly Total Debt VS Total AssetsBCT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -32.34, we must say that BCT is in the distress zone and has some risk of bankruptcy.
BCT's Altman-Z score of -32.34 is in line compared to the rest of the industry. BCT outperforms 45.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -32.34
ROIC/WACCN/A
WACCN/A
BCT.CA Yearly LT Debt VS Equity VS FCFBCT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

BCT has a Current Ratio of 0.49. This is a bad value and indicates that BCT is not financially healthy enough and could expect problems in meeting its short term obligations.
BCT's Current ratio of 0.49 is in line compared to the rest of the industry. BCT outperforms 41.67% of its industry peers.
BCT has a Quick Ratio of 0.49. This is a bad value and indicates that BCT is not financially healthy enough and could expect problems in meeting its short term obligations.
BCT has a Quick ratio (0.49) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
BCT.CA Yearly Current Assets VS Current LiabilitesBCT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.08% over the past year.
EPS 1Y (TTM)58.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.80% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.5%
EPS Next 2Y26.6%
EPS Next 3Y18.8%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCT.CA Yearly Revenue VS EstimatesBCT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2M 4M 6M 8M 10M
BCT.CA Yearly EPS VS EstimatesBCT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCT.CA Price Earnings VS Forward Price EarningsBCT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCT.CA Per share dataBCT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

BCT's earnings are expected to grow with 18.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.6%
EPS Next 3Y18.8%

More info and screens

0

5. Dividend

5.1 Amount

BCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIACELL THERAPEUTICS CORP

TSX:BCT (6/6/2025, 7:00:00 PM)

4.71

+0.17 (+3.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)06-12 2025-06-12
Inst Owners5.16%
Inst Owner ChangeN/A
Ins Owners0.78%
Ins Owner ChangeN/A
Market Cap28.83M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-95.6%
Min EPS beat(2)-172.28%
Max EPS beat(2)-18.91%
EPS beat(4)2
Avg EPS beat(4)3.82%
Min EPS beat(4)-172.28%
Max EPS beat(4)119.8%
EPS beat(8)5
Avg EPS beat(8)17.93%
EPS beat(12)6
Avg EPS beat(12)-15.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-57.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.89
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-5.02
FCFYN/A
OCF(TTM)-4.92
OCFYN/A
SpS0
BVpS-0.53
TBVpS-0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -197.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.12%
ROA(5y)-202.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z -32.34
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.12%
EPS Next Y-17.5%
EPS Next 2Y26.6%
EPS Next 3Y18.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.6%
OCF growth 3YN/A
OCF growth 5YN/A